Home | About PM | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |  Login 
Pharmacognosy Magazine
Search Article 
Advanced search 
Year : 2019  |  Volume : 15  |  Issue : 65  |  Page : 675-681

FDY003 inhibits colon cancer in a Colo205 xenograft mouse model by decreasing oxidative stress

R&D Center, Forest Hospital, Songpagu, Seoul, Republic of Korea

Correspondence Address:
Dae-Yeon Lee
Forest Hospital, 173, Ogeum-ro, Songpa-gu, Seoul
Republic of Korea
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/pm.pm_650_18

Rights and Permissions

Background: FDY003 is a traditional Korean medicine that has been developed as a complementary therapy for cancer. FDY003 contains various herbs such as Lonicera japonica, Artemisia capillaris Thunb., and Cordyceps militaris known to exhibit antioxidant and anticancer activities. Objective: The objective of this is to determine whether FDY003 represents a complementary therapy for colon cancer when it is injected using a syringe. Materials and Methods: High-performance liquid chromatography (HPLC) analysis was performed to determine the active ingredients of FDY003. The effect of FDY003 on the proliferation of Colo205 cells was investigated using the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide (MTT) assay. The antioxidant effects of FDY003 on Colo205 cells were ascertained using oxidative markers such as lipid peroxidation and 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay. Markers of apoptosis in Colo205 cells after treatment with FDY003 were also measured. Based on the in vitro results, in vivo experiments were performed using Colo205 cell-induced xenograft mouse cancer model treated with FDY003. Results: HPLC analysis revealed that FDY003 contained various active ingredients known to possess antioxidant activities. The viability of Colo205 cells was decreased by FDY003 in a concentration-dependent manner. Cancer size and weight were significantly decreased in the group treated with FDY003, similar to those in the group treated with anticancer drug irinotecan. The expression of Bcl-2-associated X protein and caspase-3 was increased in cancer tissues derived from the FDY003-treated group. Serum levels of lipid peroxidation and DPPH were also significantly increased in the FDY003-treated group. Conclusion: FDY003 represents a potential complementary therapy for cancer due to its antioxidative effects and anticancer activity.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded196    
    Comments [Add]    
    Cited by others 12    

Recommend this journal